Company intelligence / Profile preview

Institute for Integrative Therapies

Eden Prairie, Minnesota, United States

Ownership: Private
Employees: ~30
Development stage: Other

Overview

The Institute for Integrative Therapies (IIT) primarily operates as a pioneering clinical research hub and treatment center for psychedelic-assisted therapies. It is currently a key clinical site for several high-profile Phase 2 and Phase 3 trials, including the COMP006 Phase 3 study for COMP360 (psilocybin) by COMPASS Pathways and the Phase 2 study for VLS-01 (DMT) by atai Life Sciences/Beckley Psytech. Clinical data from partner Phase 2b studies (e.g., COMP360) have demonstrated significant and rapid reductions in depression symptom scores (MADRS).

Therapeutic areas: PsychiatryOther
Modalities: Small molecule
Industry: Academic Hospital/University/Research

Partnerships

atai Life SciencesBeckley PsytechCybinCOMPASS Pathways

Beyond the preview

Go deeper on Institute for Integrative Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Institute for Integrative Therapies.

Explore the full profile